Abstract
Background: Rather than a Janus Kinase 2 inhibitor (ruxolitinib), a specific thrombopoietin receptor (TpoR) inhibitor would be more specific for the treatment of myeloproliferative neoplasms due to TpoR mutations.
Objective: A cell-based phenotypic approach to identify specific TpoR inhibitors was implemented and a library of 505,483 small molecules was screened for inhibitory effects on cells transformed by TpoR mutants. Results: Among the identified hits are two analogs of 3-(4-piperidinyl) indole. The analogs showed about five-fold preferential inhibition of cell viability towards Ba/F3 cells expressing the TpoR W515L mutation compared to the parental cells. There was no significant difference in inhibition of cell viability between the TpoR wild type and the TpoR W515L mutant cells. Preferential inhibition of viability was observed in Ba/F3 cells expressing erythropoietin receptor (EpoR) when stimulated with Epo compared to stimulation with interleukin-3 (IL3). The indole analog inhibited ex vivo colony formations of primary bone marrow cells from heterozygous JAK2 V617F knock-in mice. Drug combination treatment study was performed using ruxolitinib and the indole analog. Drug synergistic effects were observed when cells were stimulated to proliferate through both the IL3 and TpoR pathways. Our compound specifically targets monoamine receptors in the rhodopsin-like receptor family of G protein-coupled receptor. Conclusion: This screen has identified a monoamine receptor inhibitor that can inhibit viability of cells with active TpoR or EpoR signalings. Drug synergism with ruxolitib is demonstrated.Keywords: Myeloproliferative neoplasms, thrombopoietin receptor, G protein-coupled receptor, phenotypic screening, drug combination study, Janus Kinase 2.
Combinatorial Chemistry & High Throughput Screening
Title:A Phenotypic Screen for Small-Molecule Inhibitors of Constitutively Active Mutant Thrombopoietin Receptor Implicated in Myeloproliferative Neoplasms
Volume: 19 Issue: 10
Author(s): Anna Ngo, Ann Zhufang Koay, Christian Pecquet, Carmen C. Diaconu, Yasmine Ould-Amer, Qiwei Huang, Congbao Kang, Anders Poulsen, May Ann Lee, David Jenkins, Andrew Shiau, Stefan N. Constantinescu and Meng Ling Choong
Affiliation:
Keywords: Myeloproliferative neoplasms, thrombopoietin receptor, G protein-coupled receptor, phenotypic screening, drug combination study, Janus Kinase 2.
Abstract: Background: Rather than a Janus Kinase 2 inhibitor (ruxolitinib), a specific thrombopoietin receptor (TpoR) inhibitor would be more specific for the treatment of myeloproliferative neoplasms due to TpoR mutations.
Objective: A cell-based phenotypic approach to identify specific TpoR inhibitors was implemented and a library of 505,483 small molecules was screened for inhibitory effects on cells transformed by TpoR mutants. Results: Among the identified hits are two analogs of 3-(4-piperidinyl) indole. The analogs showed about five-fold preferential inhibition of cell viability towards Ba/F3 cells expressing the TpoR W515L mutation compared to the parental cells. There was no significant difference in inhibition of cell viability between the TpoR wild type and the TpoR W515L mutant cells. Preferential inhibition of viability was observed in Ba/F3 cells expressing erythropoietin receptor (EpoR) when stimulated with Epo compared to stimulation with interleukin-3 (IL3). The indole analog inhibited ex vivo colony formations of primary bone marrow cells from heterozygous JAK2 V617F knock-in mice. Drug combination treatment study was performed using ruxolitinib and the indole analog. Drug synergistic effects were observed when cells were stimulated to proliferate through both the IL3 and TpoR pathways. Our compound specifically targets monoamine receptors in the rhodopsin-like receptor family of G protein-coupled receptor. Conclusion: This screen has identified a monoamine receptor inhibitor that can inhibit viability of cells with active TpoR or EpoR signalings. Drug synergism with ruxolitib is demonstrated.Export Options
About this article
Cite this article as:
Ngo Anna, Koay Zhufang Ann, Pecquet Christian, Diaconu C. Carmen, Ould-Amer Yasmine, Huang Qiwei, Kang Congbao, Poulsen Anders, Lee Ann May, Jenkins David, Shiau Andrew, Constantinescu N. Stefan and Choong Ling Meng, A Phenotypic Screen for Small-Molecule Inhibitors of Constitutively Active Mutant Thrombopoietin Receptor Implicated in Myeloproliferative Neoplasms, Combinatorial Chemistry & High Throughput Screening 2016; 19 (10) . https://dx.doi.org/10.2174/1386207319666161010163825
DOI https://dx.doi.org/10.2174/1386207319666161010163825 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
Call for Papers in Thematic Issues
Artificial Intelligence Methods for Biomedical, Biochemical and Bioinformatics Problems
Recently, a large number of technologies based on artificial intelligence have been developed and applied to solve a diverse range of problems in the areas of biomedical, biochemical and bioinformatics problems. By utilizing powerful computing resources and massive amounts of data, methods based on artificial intelligence can significantly improve the ...read more
Emerging trends in diseases mechanisms, noble drug targets and therapeutic strategies: focus on immunological and inflammatory disorders
Recently infectious and inflammatory diseases have been a key concern worldwide due to tremendous morbidity and mortality world Wide. Recent, nCOVID-9 pandemic is a good example for the emerging infectious disease outbreak. The world is facing many emerging and re-emerging diseases out breaks at present however, there is huge lack ...read more
Exploring Spectral Graph Theory in Combinatorial Chemistry
Scope of the Thematic Issue: Combinatorial chemistry involves the synthesis and analysis of a large number of diverse compounds simultaneously. Traditional methods rely on brute force experimentation, which can be time-consuming and resource-intensive. Spectral Graph Theory, a branch of mathematics dealing with the properties of graphs in relation to the ...read more
Integrating Network Pharmacology and Traditional Medicine: A New Perspective in Drug Mechanism Research
Network pharmacology is a network construction and network topology analysis strategy that combines pharmacology and pharmacodynamics. In recent years, network pharmacology has emerged as a powerful tool that can be integrated with pharmacology. Natural products commonly function in multicomponent, multitarget, and multipathway systems. Some examples encompass Ayurveda, traditional Chinese medicines ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Investigations of Malignant Mesothelioma
Current Respiratory Medicine Reviews Monofunctional Platinum (PtII) Compounds – Shifting the Paradigm in Designing New Pt-based Anticancer Agents
Current Medicinal Chemistry Mitochondrial Dysfunction in the Pathophysiology of Bipolar Disorder: Effects of Pharmacotherapy
Mini-Reviews in Medicinal Chemistry The Role of the Methoxyphenol Apocynin, a Vascular NADPH Oxidase Inhibitor, as a Chemopreventative Agent in the Potential Treatment of Cardiovascular Diseases
Current Vascular Pharmacology Synthesis, Characterization of 4-Anilino-6,7-Dimethoxy Quinazoline Derivatives as Potential Anti-Angiogenic Agents
Anti-Cancer Agents in Medicinal Chemistry Synthesis, Characterization and Evaluation of Cytotoxicity of New Aminophosphonic Acid Diesters in Human Leukemia Cells
Letters in Drug Design & Discovery Pitfalls and Solutions for the Validation of Novel Drugs in Animal Models of Disease
Current Immunology Reviews (Discontinued) Hematotoxicity Testing by Cell Clonogenic Assay in Drug Development and Preclinical Trials
Current Pharmaceutical Design Targeting Protein Degradation in the Nervous System
Current Medicinal Chemistry - Central Nervous System Agents The Quest for a Tumor Suppressor Gene Phenotype
Current Molecular Medicine Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer
Current Medicinal Chemistry Recent Advances in Molecular Image-Guided Cancer Radionuclide Therapy
Current Drug Targets Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Disorder in Milk Proteins: α-Lactalbumin. Part B. A Multifunctional Whey Protein Acting as an Oligomeric Molten Globular “Oil Container” in the Anti-Tumorigenic Drugs, Liprotides
Current Protein & Peptide Science Immunobiologic Agents in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Methotrexate: A Drug of the Future in Ulcerative Colitis?
Current Drug Targets Antibody-Based Preventive and Therapeutic Strategies Against HIV
Current HIV Research Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design Production of Lentivectors for Clinical Use
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)